Joel R. Huff

4.6k total citations
66 papers, 3.2k citations indexed

About

Joel R. Huff is a scholar working on Organic Chemistry, Molecular Biology and Infectious Diseases. According to data from OpenAlex, Joel R. Huff has authored 66 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Organic Chemistry, 29 papers in Molecular Biology and 23 papers in Infectious Diseases. Recurrent topics in Joel R. Huff's work include HIV/AIDS drug development and treatment (23 papers), HIV Research and Treatment (17 papers) and Receptor Mechanisms and Signaling (11 papers). Joel R. Huff is often cited by papers focused on HIV/AIDS drug development and treatment (23 papers), HIV Research and Treatment (17 papers) and Receptor Mechanisms and Signaling (11 papers). Joel R. Huff collaborates with scholars based in United States and Japan. Joel R. Huff's co-authors include Joseph P. Vacca, Steven D. Young, Jack E. Baldwin, George D. Hartman, Mark E. Duggan, S. J. DESOLMS, Paul Anderson, Craig W. Lindsley, William Leister and Suseela T. Sarasamma and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Nature Medicine.

In The Last Decade

Joel R. Huff

65 papers receiving 3.0k citations

Peers

Joel R. Huff

VIROL

CMN

Alfredo G. Tomasselli United States

Renée L. DesJarlais United States

Thomas D. Meek United States

Joseph P. Vacca United States

Jung‐Hsin Lin Taiwan

Steven W. Muchmore United States

John Gordon United States

Alexander M. Smondyrev United States

A. Geoffrey Skillman United States

Judith M. LaLonde United States

Alfredo G. Tomasselli United States

Joel R. Huff

2.3k ×1.7

368 ×0.3

610 ×0.8

554 ×1.0

VIROL

206 ×0.8

CMN

Citations per year, relative to Joel R. Huff Joel R. Huff (= 1×) peers Alfredo G. Tomasselli

Countries citing papers authored by Joel R. Huff

Since Specialization

Citations

This map shows the geographic impact of Joel R. Huff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel R. Huff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel R. Huff more than expected).

Fields of papers citing papers by Joel R. Huff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel R. Huff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel R. Huff. The network helps show where Joel R. Huff may publish in the future.

Co-authorship network of co-authors of Joel R. Huff

This figure shows the co-authorship network connecting the top 25 collaborators of Joel R. Huff. A scholar is included among the top collaborators of Joel R. Huff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel R. Huff. Joel R. Huff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhao, Zhijian, William Leister, R. Robinson, et al.. (2005). Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors. Bioorganic & Medicinal Chemistry Letters. 15(4). 905–909. 125 indexed citations

Lindsley, Craig W., Zhijian Zhao, William Leister, et al.. (2004). Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorganic & Medicinal Chemistry Letters. 15(3). 761–764. 415 indexed citations

Huff, Joel R. & James O. Kahn. (2001). Discovery and clinical development of HIV-1 protease inhibitors. Advances in protein chemistry. 56. 213–251. 14 indexed citations

Defeo-Jones, Deborah, Victor M. Garsky, Bradley K. Wong, et al.. (2000). A peptide–doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. Nature Medicine. 6(11). 1248–1252. 127 indexed citations

Duggan, Mark E., Le T. Duong, John Fisher, et al.. (2000). Nonpeptide α_vβ₃ Antagonists. 1. Transformation of a Potent, Integrin-Selective α_IIbβ₃ Antagonist into a Potent α_vβ₃ Antagonist. Journal of Medicinal Chemistry. 43(20). 3736–3745. 68 indexed citations

Erb, Jill M., Wayne J. Thompson, James P. Guare, et al.. (1998). Design and synthesis of N-alkylated saccharins as selective α-1a adrenergic receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 8(18). 2467–2472. 8 indexed citations

Ghosh, Arun K., Wayne J. Thompson, Paula M.D. Fitzgerald, et al.. (1994). Structure-Based Design of HIV-1 Protease Inhibitors: Replacement of Two Amides and a 10.pi.-Aromatic System by a Fused Bis-tetrahydrofuran. Journal of Medicinal Chemistry. 37(16). 2506–2508. 54 indexed citations

Hungate, Randall W., Joseph P. Vacca, Stacey L. McDaniel, et al.. (1994). Synthesis, antiviral activity, and bioavailability studies of γ-lactam derived HIV protease inhibitors. Bioorganic & Medicinal Chemistry. 2(9). 859–879. 16 indexed citations

Huff, Joel R.. (1991). HIV protease: a novel chemotherapeutic target for AIDS. Journal of Medicinal Chemistry. 34(8). 2305–2314. 360 indexed citations

10.

Pettibone, Douglas J., et al.. (1989). [3H]L-657, 743 (MK-912): A new, high affinity, selective radioligand for brain α2-adrenoceptors. Life Sciences. 44(7). 459–467. 27 indexed citations

11.

Clineschmidt, Bradley V., Douglas J. Pettibone, Victor J. Lotti, et al.. (1988). A peripherally acting alpha-2 adrenoceptor antagonist: L-659,066.. Journal of Pharmacology and Experimental Therapeutics. 245(1). 32–40. 110 indexed citations

12.

Randall, William C., Joel R. Huff, Joseph P. Vacca, et al.. (1988). [3H]L-654,284 as a probe of the central alpha2 adrenoceptor. Naunyn-Schmiedeberg s Archives of Pharmacology. 338(1). 47–52. 4 indexed citations

13.

Pettibone, Douglas J., Bradley V. Clineschmidt, Victor J. Lotti, et al.. (1987). Pharmacological profile of a new potent and specific ?2-adrenoceptor antagonist, L-657,743. Naunyn-Schmiedeberg s Archives of Pharmacology. 336(2). 169–175. 24 indexed citations

14.

Huff, Joel R., Paul Anderson, John J. Baldwin, et al.. (1985). N-(1,3,4,6,7,12b-hexahydro-2H-benzo[b]furo[2,3-a]quinolizin-2-yl)-N-methyl-2-hydroxyethanesulfonamide: a potent and selective .alpha.2-adrenoceptor antagonist. Journal of Medicinal Chemistry. 28(12). 1756–1759. 14 indexed citations

15.

Huff, Joel R., et al.. (1985). Bioactive conformation of 1-arylpiperazines at central serotonin receptors. Journal of Medicinal Chemistry. 28(7). 945–948. 17 indexed citations

16.

Saari, Walfred S., Wasyl Halczenko, Joel R. Huff, et al.. (1984). Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines. Journal of Medicinal Chemistry. 27(9). 1182–1185. 5 indexed citations

17.

Lumma, William C., et al.. (1983). Piperazinylimidazo[1,2-a]pyrazines with selective affinity for in vitro .alpha.-adrenergic receptor subtypes. Journal of Medicinal Chemistry. 26(3). 357–363. 40 indexed citations

18.

Saari, Walfred S., Mark B. Freedman, Joel R. Huff, et al.. (1978). Trichloroacetamidines, a new class of positive inotropic agents. Journal of Medicinal Chemistry. 21(12). 1283–1290. 9 indexed citations

19.

Huff, Joel R., et al.. (1965). Anodic oxidation of methanol on platinum in alkaline solution. 1 indexed citations

20.

Jasinski, Raymond, et al.. (1964). Electrochemical Oxidation of Hydrocarbons. Berichte der Bunsengesellschaft für physikalische Chemie. 68(4). 400–404. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact